Position Statements

  Date Type Size Document Notes
  October 2008     Position statement on the use of dopamine agonists in endocrine disorders - September 2007 The Society’s position statement is being reviewed in light of the information contained in the most recent issue of the MHRA Drug Safety Update (Volume 2, Issue 3 October 2008).  The Society will issue a statement in due course.
Acrobat Icon September 2006 PDF 63kb Somatostatin Analogues and GH Receptor Antagonist in Patients with Acromegaly  
Acrobat Icon April 2006 PDF 14kb Society for Endocrinology Statement regarding Thyroid Function Testing Statement on the appropriate management of thyroid disease.
Acrobat Icon March 2006 PDF 25kb Society Endorsement document A policy for dealing with requests for endorsements of other organisations' documents
SfE HTML Document June 2005 HTML   Response to NICE consultation document on Social Value Judgements  
SfE HTML Document June 2005 HTML   Use of animals in medical research  
SfE HTML Document January 2005 HTML   Hypogonadism of ageing - does low testosterone in ageing men require treatment?  
SfE HTML Document September 2004 HTML   Society statement on testosterone The Society is concerned about inappropriate testosterone therapy. This statement seeks to clarify the Society's view.
Acrobat Icon   PDF 171kb The use of growth hormone replacement in adult patients with severe growth hormone deficiency